You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023226016
Dec 2023113011
Jan 20245204
Feb 20248603
Mar 202474013
Apr 20248404
May 20247405
Jun 20244907
Jul 20247009
Aug 20243203
Sep 2024168027
Oct 20248604
Nov 20247605
Dec 20247005
Jan 20258004
Feb 202531011
Mar 2025005
Apr 2025004
May 2025008
Jun 2025003
Total13710151